Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure

Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are selected.